Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)
China
· Delayed Price · Currency is CNY 12.75
+0.50 (4.08%)
Apr 29, 2026, 3:04 PM CST
SHE:002727 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 17,003 | 17,336 | 17,462 | 16,877 | 17,124 | 14,275 | Upgrade
|
| Other Revenue | - | - | 538.72 | 503.73 | 307.42 | 312.21 | Upgrade
|
| Revenue | 17,003 | 17,336 | 18,000 | 17,380 | 17,432 | 14,587 | Upgrade
|
| Revenue Growth (YoY) | -3.76% | -3.69% | 3.57% | -0.29% | 19.50% | 15.26% | Upgrade
|
| Cost of Revenue | 11,398 | 11,680 | 12,428 | 11,798 | 11,486 | 9,320 | Upgrade
|
| Gross Profit | 5,605 | 5,656 | 5,573 | 5,582 | 5,946 | 5,267 | Upgrade
|
| Selling, General & Admin | 4,888 | 4,941 | 5,166 | 4,663 | 4,512 | 4,087 | Upgrade
|
| Research & Development | 8.88 | 10.59 | 9.71 | 10.2 | 8.74 | 5.39 | Upgrade
|
| Other Operating Expenses | -43.8 | -41.48 | 7.67 | 32.62 | 17.17 | -13.93 | Upgrade
|
| Operating Expenses | 4,853 | 4,911 | 5,190 | 4,739 | 4,628 | 4,082 | Upgrade
|
| Operating Income | 752.2 | 745.35 | 383.26 | 843.93 | 1,318 | 1,185 | Upgrade
|
| Interest Expense | -0.83 | - | -146.04 | -135.34 | -93.72 | -136.22 | Upgrade
|
| Interest & Investment Income | - | - | 47.04 | 86.48 | 7.49 | 53.52 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 0.23 | -0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -156.32 | -170.05 | -7.75 | -93.76 | 1.48 | -4.53 | Upgrade
|
| EBT Excluding Unusual Items | 595.05 | 575.3 | 276.51 | 701.32 | 1,233 | 1,098 | Upgrade
|
| Impairment of Goodwill | - | - | -26.77 | -11.65 | -12.29 | -10.97 | Upgrade
|
| Gain (Loss) on Sale of Investments | -6.15 | -7.1 | -3.43 | -8.36 | -5.72 | -5.77 | Upgrade
|
| Gain (Loss) on Sale of Assets | 9.65 | 8.79 | 3.18 | 1.12 | -13.83 | -13.41 | Upgrade
|
| Asset Writedown | -170.19 | -170.4 | -2.17 | -2.93 | -13.85 | -2.71 | Upgrade
|
| Other Unusual Items | - | - | -40 | 23.07 | 47.48 | 31.29 | Upgrade
|
| Pretax Income | 428.36 | 406.59 | 207.31 | 702.56 | 1,235 | 1,097 | Upgrade
|
| Income Tax Expense | 143.09 | 134.89 | 97.02 | 142.15 | 222 | 179.32 | Upgrade
|
| Earnings From Continuing Operations | 285.27 | 271.71 | 110.29 | 560.41 | 1,013 | 917.21 | Upgrade
|
| Minority Interest in Earnings | -6.1 | -8.27 | 3.85 | -10.97 | -2.98 | 4.38 | Upgrade
|
| Net Income | 279.17 | 263.43 | 114.14 | 549.44 | 1,010 | 921.58 | Upgrade
|
| Net Income to Common | 279.17 | 263.43 | 114.14 | 549.44 | 1,010 | 921.58 | Upgrade
|
| Net Income Growth | 764.59% | 130.80% | -79.23% | -45.60% | 9.59% | 16.66% | Upgrade
|
| Shares Outstanding (Basic) | 576 | 576 | 592 | 597 | 593 | 590 | Upgrade
|
| Shares Outstanding (Diluted) | 576 | 576 | 592 | 597 | 595 | 592 | Upgrade
|
| Shares Change (YoY) | -2.28% | -2.70% | -0.76% | 0.27% | 0.50% | 3.32% | Upgrade
|
| EPS (Basic) | 0.48 | 0.46 | 0.19 | 0.92 | 1.70 | 1.56 | Upgrade
|
| EPS (Diluted) | 0.48 | 0.46 | 0.19 | 0.92 | 1.70 | 1.56 | Upgrade
|
| EPS Growth | 784.75% | 137.21% | -79.07% | -45.75% | 9.05% | 12.91% | Upgrade
|
| Free Cash Flow | 1,584 | 1,355 | 1,466 | 1,862 | 2,148 | 1,400 | Upgrade
|
| Free Cash Flow Per Share | 2.75 | 2.35 | 2.48 | 3.12 | 3.61 | 2.36 | Upgrade
|
| Dividend Per Share | - | - | 0.300 | 0.400 | 0.400 | 0.300 | Upgrade
|
| Dividend Growth | - | - | -25.00% | - | 33.33% | - | Upgrade
|
| Gross Margin | 32.97% | 32.62% | 30.96% | 32.12% | 34.11% | 36.11% | Upgrade
|
| Operating Margin | 4.42% | 4.30% | 2.13% | 4.86% | 7.56% | 8.13% | Upgrade
|
| Profit Margin | 1.64% | 1.52% | 0.63% | 3.16% | 5.79% | 6.32% | Upgrade
|
| Free Cash Flow Margin | 9.32% | 7.82% | 8.14% | 10.71% | 12.32% | 9.60% | Upgrade
|
| EBITDA | 876.47 | 866.67 | 492.77 | 968.59 | 1,432 | 1,283 | Upgrade
|
| EBITDA Margin | 5.16% | 5.00% | 2.74% | 5.57% | 8.22% | 8.80% | Upgrade
|
| D&A For EBITDA | 124.27 | 121.32 | 109.51 | 124.66 | 114.46 | 98.08 | Upgrade
|
| EBIT | 752.2 | 745.35 | 383.26 | 843.93 | 1,318 | 1,185 | Upgrade
|
| EBIT Margin | 4.42% | 4.30% | 2.13% | 4.86% | 7.56% | 8.13% | Upgrade
|
| Effective Tax Rate | 33.40% | 33.17% | 46.80% | 20.23% | 17.98% | 16.35% | Upgrade
|
| Revenue as Reported | - | - | 18,000 | 17,380 | 17,432 | 14,587 | Upgrade
|
| Advertising Expenses | - | - | 62.9 | 49.55 | 49.28 | 42.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.